The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective

Lenvatinib is an oral multikinase inhibitor indicated for the first-line treatment of unresectable hepatocellular carcinoma (uHCC). In the Phase III REFLECT trial, lenvatinib was noninferior in the primary endpoint of overall survival versus sorafenib, the only systemic therapy funded in Canada prio...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyers, Brandon M., Vogel, Arndt, Marotta, Paul, Kavan, Petr, Kamboj, Laveena, Pan, Janice, Geadah, Marc, Trueman, David, Sabapathy, Suthakar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929650/
https://www.ncbi.nlm.nih.gov/pubmed/33681090
http://dx.doi.org/10.1155/2021/8811018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929650/
https://www.ncbi.nlm.nih.gov/pubmed/33681090
http://dx.doi.org/10.1155/2021/8811018

Ejemplares similares